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The Mechanism KSHV Plays in Mesenchymal to Endothelial Transition
in Kaposi Sarcoma
Abstract
To gain a better understanding of the tumorigenesis of Kaposi sarcoma (KS) it is essential to understand the
role KSHV plays in the mesenchymal-to endothelial transition (MEndT). PROX1 in human related cancers
can act as a transcriptional repressor or activator that leads to several effects on cellular differentiation and
proliferation1-3. PROX1 upregulation may play a significant role in the MEndT and in turn effect the
tumorigenesis of KS. This study was conducted to evaluate if PROX1 is upregulated by KSHV. To test this,
human GMSCs and human PDLSCs were used, as well as 293T cells. They were transfected at 70%
confluency using Lipofectamine 3000 with a PROX1 promoter, pPROX1, cloned into a pGL3 promoter. The
cells were then infected using recombinant green fluorescent protein (GFP) expressing KSHV (rKSHV.219) .
A luciferase assay was conducted to measure expression of pPROX1. The samples were lysed and collected at
different time points (24, 36, 48 hours). Results show that in 293Tcells KSHV infected cells do not exhibit
noticeable luciferase signal activation of pPROX1 at 24, 36, and 48 hours post infection, PDLSCs show a
slight increase in luciferase signal in KSHV+ pGL3-PROX1 v6 is at 24, 36 and 48 hours post infection, while
in KSHV infected GMSCs do not exhibit noticeable luciferase signal activation of pPROX1 at 24,36 and 48
hours. In conclusion, there is no significant activation of pPROX1 in KSHV infected 293Tcells, PDLSCs, and
GMSCs. Future experiments that are warranted would be assessing the upregulation of PROX1 via Western
Blot and RT-PCR.
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Abstract: 
 
To gain a better understanding of the tumorigenesis of Kaposi sarcoma (KS) it is 
essential to understand the role KSHV plays in the mesenchymal-to endothelial 
transition (MEndT). PROX1 in human related cancers can act as a transcriptional 
repressor or activator that leads to several effects on cellular differentiation and 
proliferation1-3. PROX1 upregulation may play a significant role in the MEndT and in turn 
effect the tumorigenesis of KS. This study was conducted to evaluate if PROX1 is 
upregulated by KSHV. To test this, human GMSCs and human PDLSCs were used, as 
well as 293T cells. They were transfected at 70% confluency using Lipofectamine 3000 
with a PROX1 promoter, pPROX1, cloned into a pGL3 promoter. The cells were then 
infected using recombinant green fluorescent protein (GFP) expressing KSHV 
(rKSHV.219) . A luciferase assay was conducted to measure expression of pPROX1. 
The samples were lysed and collected at different time points (24, 36, 48 hours). 
Results show that in 293Tcells KSHV infected cells do not exhibit noticeable luciferase 
signal activation of pPROX1 at 24, 36, and 48 hours post infection, PDLSCs show a 
slight increase in luciferase signal in KSHV+ pGL3-PROX1 v6 is at 24, 36 and 48 hours 
post infection, while in KSHV infected GMSCs do not exhibit noticeable luciferase signal 
activation of pPROX1 at 24,36 and 48 hours. In conclusion, there is no significant 
activation of pPROX1 in KSHV infected 293Tcells, PDLSCs, and GMSCs. Future 
experiments that are warranted would be assessing the upregulation of PROX1 via 
Western Blot and RT-PCR. 
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Introduction: 
 
Kaposi sarcoma, KS, is considered a vascular neoplasm. It can be used as a model to 
study many aspects of carcinogenesis including cancer immunology, viral oncogenesis 
and angiogenesis. KS can involve the mucosa, skin, and viscera 4,5. Kaposi's sarcoma-
associated herpesvirus, KSHV, encodes several genes that target cellular oncogenic, 
survival and tumor suppressor genes, but the mechanism remains unclear 6. Tumor 
cells infected with KSHV manifest the classic spindle shape morphology, expressing 
lymphatic endothelial, vascular endothelial and mesenchymal markers7 8. 
 
Immunohistochemical features of KS include mesenchymal and precursor markers, 
which suggest that KS could originate from pluripotent mesenchymal stem cells, MSCs. 
KS has been shown to confer MSCs with KS associated phenotypes such as 
angiogenesis, endothelial cell linage and cytokine/chemokine production 9 3. There is a 
need to better understand how KSHV infection reprograms infected MSCs by activating 
numerous genes to start the mesenchymal to endothelial transition, MEndT. KSHV 
affects the expression of several linage specific genes. In MSCs, MEndT related genes 
(PDPN, EDNRA, and PML D106) were found to be upregulated in response to KSHV 
infection. PROX1 in human related cancers can act as a transcriptional repressor or 
activator that leads to several effects on cellular differentiation and proliferation. PROX1 
upregulation might play a significant role in the tumorigenesis of KS and further studies 
are warranted to evaluate its role. 
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Cellular origin of Kaposi sarcoma: 
Despite many studies that have been done to establish the cellular origin of KS, the 
origin of KS cells remain a mystery. Tumor cells infected with KSHV manifest the classic 
spindle shape morphology, expressing lymphatic endothelial, vascular endothelial and 
mesenchymal markers7. Studies supporting the theory that KS is of endothelial cell 
linage argue that evidence indicate the lymphatic origin. KSHV-infected ECs display 
increased proliferative, angiogenic and migratory capacities which account for KS 
oncogenesis. Different studies have reported that sarcoma cells express a number of 
endothelial cell, EC, markers. For example, CD31, CD34, and FACTORVIII are 
expressed in both SC and EC lines, but they also express  lineage specific signatures of 
smooth muscle cells, α-SMA), monocytes, macrophages, dendritic cells, fibroblasts and 
mesenchymal cells4,10. 
 
The gene expression signature of KSHV infected cells might indicate an endothelial 
origin, but it is still a matter of debate whether the original precursor belongs to blood or 
lymphatic lineage. KSHV infected lymphatic ECs, LEC’s, or KSHV-LECs are more 
similar to immature blood ECs, BECs, than uninfected LECs by the virus triggering 
cellular reprogramming towards a more pluripotent state. KSHV-infected BECs 
however, express lower levels of blood vascular markers, like Cxcr4 and Neuropilin-1 
show an increase in lymphatic markers like Prox1, Vegfr3, Podaplanin and Lyve1. 
KSHV infection of ECs reverses the differentiated EC fate and recovers the pluripotent, 
even mesenchymal stem-cell lineage with mixed identity. As a result, KSHV-infected 
ECs display tumorigenic properties, i.e. increased angiogenic, invasive and migratory 
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abilities, and while not fully immortalized, they exhibit a growth advantage over their 
uninfected counterparts 11. 
 
Several observations suggest that LECs, rather than BECs, are the main precursor of 
SCs. First, the localization of KS lesions in tissues rich in lymphatics (skin and mucosa). 
Secondly, cultured KSHV-LECs exhibit elongated (spindle) morphology, resembling KS-
SCs, whereas in BECs the morphology is not significantly altered by KSHV infection. 
Furthermore, LECs can be more efficiently infected and harbor a higher viral copy 
number. The comparison of the gene expression profile of nodular KS lesion with those 
of BECs and LECs showed that the KS signature resembles more like LECs rather than 
BECs. Moreover, three-dimensional cultures of KSHV-LECs, has been shown to 
recapitulate many of the features found in the KS lesions. The differential expression of 
endothelial and mesenchymal markers in virus-infected cells and the tumorigenic 
invasiveness increases in the 3D matrix11,12. 
 
Regardless, the presence of KSHV-infected BECs in KS lesions cannot be ruled out. 
KSHV-BECs are found in early KS patches, whereas KSHV-positive cells line aberrant 
blood vessels. While the advanced lesions does represent the majority of the tumor 
mass, KSHV-SCs were not found in blood vessels. One could hypothesize that KSHV 
infects both BEC and LEC at the early stages of the disease, but then KSHV-LECs are 
more susceptible hosts for the virus, propagate more efficiently, and become the 
predominant cell type in the advanced lesion. In agreement with this hypothesis, a study 
in which PROX1 expression, a marker of lymphatic differentiation, was investigated in 
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AIDS-oral KS. Here, PROX1, almost absent in early KS patches, increased significantly 
in advanced plaque and nodular stages. Another possibility is that KS-SCs originate 
from the infection of circulating EC precursors (ECPs), CD34-positive bone marrow-
derived cells that aggregate to angiogenic sites where they then differentiate into 
mature ECs. In support for this hypothesis, ECPs isolated from KS patients were found 
positive for KSHV, retained the virus after several passages, and were able to sustain 
lytic replication. Also, ECPs from KS patients displayed higher angiogenic potential in 
vitro, KSHV-positive, CD34+, adherent SCs were found in the blood mononuclear 
fraction, and finally the multifocal nature of KS lesions occur independently in different 
areas of the body, preferentially in surgical scar sites and other sites of previous 
inflammation angiogenesis, which are areas where ECPs are recruited5,13. Recent 
emerging studies now support the theory that the transition could be mesenchymal to 
endothelial. Immunohistochemical features of KS include mesenchymal and precursor 
markers, which suggest that KS could originate from pluripotent mesenchymal stem 
cells, MSCs. A study conducted by Yuan et al. has shown that  KS can confer MSCs 
with KS associated phenotypes such as angiogenesis, endothelial cell linage, and 
cytokine/chemokine production9. There is a need to better understand how KSHV 
infection reprograms infected MSCs by activating numerous genes to start the 
mesenchymal to endothelial transition (MEndT). KSHV affects the expression of several 
linage specific genes. In MSCs (MEndT) related genes (PROX1, PDPN, EDNRA, PML, 
PGF, and TGF-b3) were found to be upregulated in response to KSHV infection while in 
KSHV infected LECs PROX1 was found to be down regulated and no change was 
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noted in the levels of (PDPN, EDNRA, PML, PGF, and TGF-b3). PROX1 upregulation 
triggers the tumorigenesis of KS14-16. 
 
The role of PROX1:  
The Prospero Homeobox 1 gene PROX1 is the vertebrate homologue of Drosophila 
prospero gene. It is a transcription factor that plays an important role in the development 
of the liver, central nervous system, pancreas and in lens fiber elongation. It is a master 
regulator that influences the healthy embryonic development of lymphatic vasculature 17 
18 19. The role PROX1 plays in Kaposi sarcoma and cell differentiation is still poorly 
understood. A review conducted by Cancian et al. stated that the up regulation of 
PROX1 in KSHV infected BECs switches on LEC-specific genes in the blood 
vasculature 8. If PROX1 is silenced during the infection of BECs this inhibits KSHV-
mediated upregulation of many key lymphatic genes, demonstrating that PROX1 is 
important for KSHV driven BEC-to-LEC reprogramming8. The expression of PROX1 is 
one of the first indications that the molecular program leading to lymphatic vasculature 
formation is starting. This primary expression followed by migration of PROX1- 
expressing endothelial lymphatic progenitor endothelial cells that gradually increase the 
expression of lymphatic markers like VEGFR-3 and down regulates the expression of 
blood vascular genes like Lamninin and CD34. This confirms the important role of 
PROX1 is established by stimulating undifferentiated endothelial cells to commit to a 
lymphatic fate1,17,20. 
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Studies have shown that the lymphatic and blood vasculature are greatly similar since 
both are lined with endothelial cells and share some markers. Furthermore, the 
expression of additional gene products might be enough to convert endothelial cells if 
required to blood vascular phenotype into a lymphatic phenotype. Through this, PROX1 
has been determined as a master regulator of the molecular switch, since its expression 
is enough to override the blood vasculature phenotype in primary human endothelial 
cells by promoting a lymphatic endothelial phenotype instead18,21. It is thought that 
PROX1 plays an essential role as a switch necessary to promote and maintain 
lymphatic endothelial cell identity and suppress blood vascular endothelial cell identity. 
Variations in the levels of PROX1 expression are triggers to differentiate lymphatic 
endothelial cell phenotype into a blood vascular endothelial cell phenotype, which 
verifies that PROX1 activity is required not only for cell type specification but also to 
preserve the mature differentiated lymphatic endothelial cell phenotype. Moreover, the 
lymphatic endothelial cell phenotype is lost when PROX1 is expressed below a certain 
threshold. In embryonic and mature lymphatic vasculature, constant PROX1 expression 
is necessary to maintain the lymphatic endothelial cell identity and suppression of 
default blood vascular endothelial cell identity13,18.  PROX1 could act as a master switch 
in this process and the study of cellular reprograming and plasticity as well as gene 
modulation would help to better understand this mechanism14,17,22,23. 
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Study design : 
Study Objective:  The objective of this study is to understand the potential effects that 
KSHV has on specific gene expression and the invasive and aggressive nature of the 
biology of KS in vivo.  
 Hypothesis: 
• PROX1 could be expressed at higher levels in KSHV infected gingival 
mesenchymal cells (GMSC) and periodontal mesenchymal cells (PDLSC), in 
comparison to uninfected GMSCs and PDLSCs. 
• KSHV infection could increases expression of PROX1 in GMSC and PDLSC. 
This will be tested using a luciferase assay on both mesenchymal and 293T 
cells. 
 
Significance: 
Grasp an understanding of the function of PROX1. The pathological role PROX1 
plays in KS  is poorly understood, could lymphatic reprograming be a goal of PROX1 
upregulation or a byproduct in Kaposi sarcoma? Many studies have shown that PROX1  
in some cancers is oncogenic and in others plays a tumor suppressive 22. Therefore, the 
tissue microenvironment and cell type may be important for PROX1 to be oncogenic or 
tumor suppressive 24. The proposed project will help to understand the key role PROX1 
plays in KS.  
 
Significant impact on the understanding of Kaposi sarcoma (KS). KS is undeniably 
the most common malignancy HIV patients suffer from. It is characterized by abnormal 
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inflammation neoagniogensis and proliferation of spindle cells 4,5. Examining the cellular 
origin of KS and the method in which the tumor affects the normal differential pathways 
through specific transcriptional factors like PROX1 is crucial to understanding the 
diseases progression17. The proposed project will shed light on the progression of 
Kaposi sarcoma.  
 
Design for new treatments and therapies. The method in which PROX1 affects 
essential pathways in tumorigenesis is not well comprehended22. The aim of this project 
is to shed light on the underlying mechanisms affected by PROX1 in Kaposi sarcoma 
which could contribute to the development of new therapies and treatments. 
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Chapter 2 
 
Materials and methods: 
RNA-Seq data analysis. RNA-seq data was aligned against human (GRCh38.p12) 
genome and transcriptomes using Hisat2 algorithm. Raw counts were converted to log2 
(5+count) values and quantile normalized to use in Principle Component Analysis and 
gene expression heatmaps. Significance and fold change of differential expression 
between lesion and control samples was estimated using the DESeq2 method on raw 
values and genes with false discovery rate (FDR) <5% were considered as significant. 
An additional threshold of 5-fold was used to enumerate a set of most-changed genes 
between conditions. Pearson correlation was used to test associations between KSHV 
transcript loads in cultures for significantly differentially expressed genes. Correlations 
with p<0.05 were considered significant. Expression heatmaps were plotted in Microsoft 
Excel using normalized values centered versus average across all samples. 
Differentially expressed genes were then used for GeneOnotology analysis using 
Panther14.1 classification system.  
 
Culturing of iSLK-BAC16 cells and Virus Purification. iSLK-BAC16 cells were 
seeded at 2.1 x 106 cells/flask of a T75 flask or ∼70% confluence. iSLK-BAC16 cells 
were cultured in Dulbecco's modified Eagle's medium (DMEM) that was supplemented 
with 10% fetal bovine serum and in the presence of 1 μg/ml puromycin, 250 μg/ml 
G418, and 1,200 μg/ml hygromycin B.  Cells were incubated at 37°C with a humidified 
atmosphere of 5% CO2. 
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iSLK-BAC16 cells were induced in the presence of both doxycycline (1 μg/ml) and 
sodium butyrate (1 mM) and the absence of hygromycin, puromycin, and G418. Four 
days later, supernatant was collected and cleared of cells and debris by centrifugation 
(950xg for 10 minutes at 4°C) and filtered (0.45 μm). Virus particles were pelleted by 
ultracentrifugation (25,000 g for 3 hours at 4°C) with a 5mL 25% sucrose cushion using 
an SW32 Ti rotor. Pellets were resuspended in 200uL of 1xPBS and frozen at -80°C for 
long term storage.  
 
Quantification of Virions. Following pelleting of virion particles, to remove 
contaminating DNA outside viral particles, the concentrated viruses were treated with 
Turbo DNase I (Ambion) at 37°C for 1 h, followed by proteinase K digestion. Virion DNA 
was extracted with phenol-chloroform, precipitated with ice-cold ethanol, and then 
dissolved in Tris-EDTA (TE) buffer. The KSHV genomic copy number was quantified by 
real-time PCR using SYBR green kit with primers for the detection of LANA (forward, 5′-
CGCGAATACCGCTATGTACTCA-3′; reverse, 5′-GGAACGCGCCTCATACGA-3′). Viron 
samples were loaded onto a MicroAmp Optical 96-well reaction plate in an increasing 
10-fold serial dilution. CT values were compared to a known LANA standard that was 
isolated through plasmid digest and gel isolation to isolate the LANA fragment following 
agarose gel electrophoresis.  
 
Promoter Identification. Ensembl database using GRCh38.p12 (Genome Reference 
Consortium Human Build 38), INSDC Assembly GCA_000001405.27, Dec 2013 was 
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used to identify the promoter and promoter flanking region coordinates, 
ENSR00000386083. Promoter sequence was then determined using NCBI FASTA 
viewer.  
 
Isolation of Human Genomic DNA from 293T cells. 293T cells were cultured were 
cultured in DMEM supplemented with 10% fetal bovine serum with 100U/mL 
penicillin/streptomycin antibiotic solution and harvested by using 0.05% (w/v) Trypsin in 
0.53 mM EDTA solution. DNA was isolated using QIAamp DNA Mini Kit (Qiagen) 
following the provided kit protocol.  
 
Cloning PROX1 Promoter Region. Primers used to amplify the PROX1 promoter 
region from human genomic DNA were designed to have a four nucleotide non-
homologous nonsense overhang (CCCC or GCGC) followed by NheI digest site for the 
forward primer and HindIII digest site for the reverse primer. pPROX1 version 6 primers 
(forward, 5’- CCCCGCTAGCATTTGGACTGGAGATAAACTGGGA-3’ and reverse, 5’-
GGGGAAGCTTAGGTACCACCCAGACGAGA-3’). Version 7 primers (forward, 5’-
GCGCGCGCTAGCCCAGATGTTTGCAACATATA-3’ and reverse, 5’-
GCGCGCAAGCTTGCAGGAGAAAGAAGGAAAGG-3’). PCR amplification was done 
using GoTaq Green Master Mix (Promega) and conducted using the provided 
manufacturer’s protocol.   
 
Phenol-Chloroform Extraction. The PCR product of pPROX1, either version 6 or 
version 7, was separately pooled to a total volume of 500uL each. One equal volume of 
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phenol:chloroform:isoamyl alcohol (25:24:1) was added to each sample and vortexed 
for 20 seconds. Phase separation was done by centrifugation at room temperature for 
15 minutes at 16,000g. The aqueous phase was transferred to a clean Eppendorf tube 
and solution was brought to 3M Ammonium acetate (NH4OAc) and brought to 1.2mL 
using 100% isopropanol. Samples were incubated at -20°C overnight to precipitate the 
DNA from the samples. Samples were centrifuged at 4°C for 30 minutes at 16,000g to 
pellet the cDNA. Pellets were washed by in 70% ethanol.  Pellets were air dried and 
resuspended in 30uL of 1xTE buffer. DNA concentrations were then quantified on 
NanoDrop. 
 
Restriction Enzyme Digestion. Purified PCR pPROX1 samples and PGL3 were then 
subjected to NheI and HindIII double restriction enzyme digest. Reaction was set up 
according to recommended New England Biolabs (NEB) protocol using Restriction 
Enzyme Buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM, MgCl2, 1 mM DTT final 
concentration). The final concentration of glycerol in the digest reaction was less than 
5% to minimize the possibility of star activity. Reaction was done for 1hr at 37C, PCR 
pPROX1 products were then purified using phenol-chloroform extraction as described 
previously. PGL3 plasmid was then loaded onto a 1% agarose gel for gel band 
extraction. 
 
Gel Electrophoresis and Gel Band Extraction. A 100mL 1% melted agarose gel in 1x 
tris-acetate-EDTA (1x TAE) was prepared with ethidium bromide (EtBr) to a final 
concentration of approximately 0.5 μg/mL. Samples and standard gel ladder was loaded 
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and run at 100 volts for 1 hour. Digested PGL3 gel band (4818bp) was identified under 
UV light and excised using a sterile scalpel. Gel fragment containing desired DNA 
product was then used in QIAquick Gel Extraction Kit following provided manufacturer's 
protocol (Qiagen).  
 
T4 Ligation. Purified digested plasmid and promoters were ligated following 
manufacturer's provided protocol (NEB) for cohesive sticky end ligation using a molar 
ratio of 1:3 vector to insert. Reactions were incubated at 16°C overnight, then heat 
inactivated at 65°C for 10 minutes. Samples were chilled on ice and 2μl of the reaction 
was transformed into 50 μl of competent cells. 
 
Preparing Competent Cells for Transformation. The Escherichia XL1-Blue strain 
genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIq Z∆M15 
Tn10 (Tetr )]. Bacterial strain was streaked from frozen glycerol stock on Luria-Bertani, 
LB, plates and incubated at 37°C overnight. Individual colony was picked and cultured 
in 2mL liquid LB media and incubated at 37°C overnight under constant agitation. 1mL 
of inoculate was used to culture 100mL LB and incubated at 37°C under constant 
agitation for ~2 hours until torrid OD600=0.25-0.4. Culture was chilled on ice for 15 
minutes and centrifuged at 3000g for 10 minutes at 4C. Pellet was resuspended in 
40mL ice cold 0.1M CaCl2. Pellet was resuspended in 8mL of 0.1M CaCl2 Solution plus 
15% Glycerol. Cells were aliquoted and flash frozen in liquid nitrogen prior to long term 
storage at -80C. 
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Luria-Bertani ampicillin culture plates. 15 g of Bacto-agar was dissolved in 1.0 L of 
LB medium and sterilize by autoclaving. Solution was cooled to 50°C in a temperature-
controlled water bath and 0.50 mL of 100 mg/mL ampicillin was added prior to pouring 
into plates.  
 
Transformation and Screening. Competent cells were thawed on ice, 50µl of 
competent cells were added to DNA solution and gently mixed. Mixture was incubated 
on ice for 30 minutes then subjected to heat shock at 42°C for 30 seconds. Samples 
were cooled on ice briefly and 950µl of room temperature LB media was added to the 
transformation reaction. The transformation was incubated at 37°C for 60 minutes under 
constant agitation. 100 µl of the transformation reaction was then plated onto LB-amp 
plates.  
 
Individual colonies were picked and streaked onto LB-amp plates and incubated 
overnight at 37°C. An individual colony from each transformant was then picked and 
cultured in liquid LB-amp overnight at 37°C under constant agitation. Cultures were then 
pelleted and plasmid was extracted using plasmid miniprep kit following manufacturer's 
supplied protocol (Qiagen). Plasmids were then digested with NheI and/or HindIII using 
previously described methodology and then run on 1% agarose gel as previously 
described. Positive transformants were then sequenced at University of Pennsylvania 
DNA Sequencing Facility using their provided instructions.  
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CsCl Isolation of Plasmid DNA. An individual colony was picked and cultured in 5mL 
liquid LB-amp media and incubated at 37°C overnight under constant agitation. 5mL 
culture was used to inoculate 500 ml LB-amp in 2L flask and incubated at 37°C 
overnight under constant agitation. Culture was centrifuged for 15 minutes at 3000g. 
Pellet was resuspended in 20mL of resuspension solution (55.5mM glucose, 25mM 
Tris-Cl, 10mM EDTA, 0.002g/mL lysozyme). Cells were lysed using 40mL of lysis 
solution (0.16N NaOH and 0.8% SDS) and incubated on ice for 15 minutes. Reaction 
neutralized using 30mL of neutralizing solution (0.75M potassium acetate and 11.5% 
glacial acetic acid). Solution was then centrifuged at 4°C for 30 minutes at 5000g. 
Supernatant was then decanted through four layers of cheesecloth into a new centrifuge 
bottle. To precipitate out the DNA, 54mL of isopropanol was added and incubated for 10 
minutes at room temperature and centrifuged for 30 minutes at 5000g at 4°C. The 
supernatant was discarded and pellet was washed in 70% ethanol. Pellet was air dried 
and resuspended in 20mL 1xTE buffer and incubated at 4°C overnight to dissolve the 
pellet. Solution was then used to dissolve 20g of CsCl and 1.5mL of 10mg/mL ethidium 
bromide was added. Solution was centrifuged for 15 minutes at 1000g to pellet 
undissolved ethidium bromide particles. Supernatant was transferred to Beckman 
Quick-Seal 25x89mm centrifugation tube and overlaid with 20mL of mineral oil. 
Beckman tubes were heat sealed and centrifuged using Ti70 rotor at 45,000rpm @18C 
for 48hr. 
 
Beckman tubes were then illuminated with UV light to identify separated bands, the 
upper plasmid band was extracted using 18 gauge hypodermic needle attached to a 
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5mL sterile syringe and contents were added to butanol to separate ethidium bromide. 
Water-butanol phase separation was repeated until clear and liquid layer containing 
plasmid was then subjected to dialysis in buffer (10mM Tris-HCl pH 8.0, 1mM EDTA) 
overnight and then purified using phenol-chloroform purification as previously described 
and concentration was measured by NanoDrop.  
 
PDLSC and GMSC Culturing. Periodontal ligament stem cells, PDLSCs, or Gingival 
mesenchymal stem cells, GMSCs, passages 1-7 were cultured in MEM-alpha 
supplemented with 15% fetal bovine serum with 100U/mL penicillin/streptomycin 
antibiotic solution, 0.1mM L-ascorbic acid phosphate, and 2mM glutamine. Media was 
replaced every 48 hours during culturing. Cells were incubated at 37°C with a 
humidified atmosphere of 5% CO2. PDLSCs more than the seventh passage were not 
used in any of the identified experiments. 
 
Lipofectamine LTX/ STEM/ 2000/ 3000 Transfection. PDLSCs, GMSCs, and 293T 
cells were plated such that they were 70% confluent at the time of transfection. 
Lipofectamine reagent based transfection was performed according to manufacturer’s 
provided protocol (ThermoFisher). Cells were plated on 24 well plate and the 
manufacturer’s recommended volume of Lipofectamine reagent plasmid DNA was used 
per transfection well.  
 
De Novo Infection. Cells to be infected were plated 24 hours prior to infection in either 
a 6-well or 24-well plate at 1.2 x 106 or 0.24x106 cells, respectively. Virion concentration 
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was calculated through genomic isolation and real-time PCR as previously described. 
Virus particles were added to each well at a MOI 50 viral copies/cell. Polybrene was 
added to each to-be infected well at a final concentration of 5mg per milliliter of total 
media. Cell plates were centrifuged at 450 x g for 1 hour at 25°C and incubated at 37°C 
with a humidified atmosphere of 5% CO2 for 2 hours. After the combined total of 3 
hours, media was aspirated and replaced with fresh pre-warmed media. Infection rate 
was monitored and measured visually by use of  a Nikon TE2000-U fluorescence 
microscope to assess GFP expression.  
 
Luciferase Assay. Cells were cultured such that at the time of transfection the cells 
were 70% confluent by the time of transfection, 24 hours post-transfection the cells 
were then subjected to KSHV infection. Following 24, 36, and 48 hour timepoints post 
infection, samples were subjected to luciferase assay with Promega's Dual-luciferase 
assay kit. Each condition was done in triplicate and each sample was measured in 
duplicate for both luciferase and renilla levels 25. 
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Chapter 3 
Results:  
KSHV affects the expression of several linage specific genes. The Yuan lab has shown 
that in MSCs, mesenchymal-to endothelial transition (MEndT)-related genes (such as 
PDPN, EDNRA, PML, PGF and TGF-b3) are up-regulated in response to KSHV 
infection 15 . 
 
I hypothesize that PROX1 could be upregulated in KSHV infected gingival 
mesenchymal cells (GMSC), periodontal mesenchymal cells(PDLSC) in 
comparison to uninfected GMSCs and PDLSCs. To test this human GMSCs and 
human PDLSCs  will be used as well as 293T cells. The human PDLSCs and GMSCs 
were obtained from patients aged (12-25) years old. They were a kind gift from the Shi 
lab. Cells from the second and sixth passages were used. They were transfected at 
70% confluency using Lipofectamine  with PROX1 promoter cloned into a pGL3 
promoter. The cells were then infected using recombinant green fluorescent protein 
(GFP) expressing KSHV (rKSHV.219) The infectivity rate was evaluated by the rate of 
the cells converted to GFP positive. They were then lysed to be collected at different 
time points (24,36,48) hours. A luciferase assay was then conducted to measure 
expression of pPROX1. 
 
Virus purification: 
To obtain the KSHV virus iSLK-BAC cells containing KSHV BAC16, derived from the 
rKSHV.219 virus were cultured. These cells stem from KSHV and Epstein-Barr virus-
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coinfected JSC1 primary effusion lymphoma (PEL) cells. KSHV BAC16 virus stock was 
produced as mentioned in the Materials and Methods section. Six T75 surface 75 cm2 
flasks were used to  seed  iSLK cells harboring BAC16 at ∼70% confluence. They were 
then treated with 1mM sodium butyrate and 1 μg/ml of doxycycline for 96 hours. The 
virus-containing supernatants were then collected and concentrated via centrifugation 
using a SW32 rotor. The residual medium was then used to resuspend the virus pellets. 
T293 cells were then infected with BAC16 virus stock and analyzed by fluorescence 
microscopy and flow cytometry at 24 hour post infection. 
 
Viral Titer: 
To develop a standard curve from a known control a linearized plasmid containing the 
KSHV gene Latency Associated Nuclear Antigen, LANA, (3486bp) was used with 
primers specific to the LANA coding sequence amplifying a 1080bp long region with a 
known concentration (5ng/ μl). In order to develop a standard curve, the initial sample 
1:20 was diluted, such that the first measurement contains 0.25ng of total DNA and 
proceed in a 1:5 serial dilution for twelve data points, done in triplicate. (Therefore the 
last data point will only have 5.12E-09 ng total DNA. The results are then plotted such 
that the Y-axis plots the mean Ct value of the triplicate. Where Ct (cycle threshold) is 
defined as the number of cycles required for the fluorescent signal to cross the 
threshold (i.e. exceeds background level). However, the X-axis is not the total DNA 
concentration of the well, but the log10 value of the total concentration (0.25ng is 
equivalent to -0.60206). 
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From here a line was plotted and the formula was calculated for a line (y=mx+b). In this 
case the slope (m) is -3.3251003 and the y-intercept (b) is 4.73174082. The efficiency 
of the reaction was calculated through the efficiency formula [10(-1/m)-1]*100, which in 
this case is 99.8677889%. We can also determine the copy number (number of 
molecules) for a given concentration of control sample through the formula 
Molecules=[Xng*6.0221E23]/[(1080bp*617.96g/mol)*10E9ng/g]. Which is simply mass 
multiplied by Avogadro's number divided by the molecular mass of the DNA sample. 
While the average molecular mass of one base pair is 660 g/mol for the approximate 
mass of a whole double-stranded DNA molecule, the exact molecular mass of this 
LANA sequence is 617.96g/mol as determined by its genetic sequence.  
 
Since we have the known concentration per each data point and the Ct value, we can 
correlate the copy number (number of molecules) for each Ct value of the standard. 
With this, the copy number of the unknown KSHV sample at each Ct value in the serial 
dilution can be determined by reapplying these formulas. Furthermore, the Ct value was 
plotted against the log10 value of the observed concentration of each sample virus. It 
was noticed that 1μl of the July virus is 9.46E+05 viroid per microliter. While the August 
and February samples are 2.21E+06 and 2.51E+06 viroids per microliter, respectively. 
MOI is related to KSHV by the following formula: Multiplicity of infection (MOI) = KSHV 
units of virus used for infection / number of cells.  Note, for a MOI of 50 for the Yuan’s 
lab’s protocol, we require 2.5E+06 viroids per microliter. Which explains why the July 
KSHV is unable to successfully infect our cell cultures. Given that a 12 well plate has 
0.5x106 cells at confluency and is infected by a MOI of 50: 25x106  total KSHV particles 
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are required. If 10 μl volume of viral solution is used, that must mean the KSHV 
concentration must be 2.5x106 /ul. 
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Figure1: Serial dilution of newly purified virus fits to standard curve 
 
Figure 1: Comparing  a 1:5 serial dilution of our lab’s LANA standard to three viral DNA samples, also 
done in a 1:5 serial dilution. The KSHV purification performed in July 2018 was found to be 
unsuccessful in infecting our cell samples, while both the August and February samples were able to 
successfully infect our cell samples following a standardized protocol.  
 
Cycle Threshold 
(Ct) 
Log10 Concentration (ng/ μl) 
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Overall infection efficiency: 
An infection was done to compare a freshly purified virus (February virus) to a virus 
previously proven to be effective in the Yuan lab (August virus). The infection efficiency 
was measured as >90%  Infectivity rate was measured by counting the total amount of 
cells observed in a given visual filed and comparing it to the amount of GFP positive 
cells observed within the same visual field if n=100 cells and 80 cells were GFP positive 
then 80/100 =80%. The cells were evaluated at different time points. Figure 2 and 
Figure 3 An experiment was conducted to evaluate the infection efficiency in 
PDLSCS,GMSCS, and 293 cells. Figure 4 
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Figure 2: Comparing August virus to February virus infectivity rate in PDLSCs 
August virus 
KSHV pre- 
infection 
  
August virus 
KSHV  
24hr post 
infection 
  
August virus 
KSHV  
48hr post 
infection 
  
Figure 2: August virus is able to successfully infect PDLSCs. Cells are imaged using a 10x/0.25 objective 
inverted fluorescent light microscope. 
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Figure 3: Comparing August virus to February virus infectivity rate in PDLSCs 
February 
virus KSHV 
pre-infection 
  
February 
virus KSHV 
24hr post 
infection 
  
February 
virus KSHV 
48hr post 
infection 
  
Figure3: February virus is sucessfully able to infect PDLSCs. Cells are imaged using a 10x/0.25 
objective inverted fluorescent light microscope. 
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Figure 4: February virus is able to establish a successful infection in PDLSCs, 
GMSCs, and 293T cells                                
PDLSC 
 
  
GMSC 
  
293T 
  
Figure 4: The February virus infection efficiency  in PDLSC:80%, GMSC:90%, and 293T cells 
90%.n=100 cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Cloning: 
The promoter region of PROX1 (pPROX1) was cloned into a luciferase reporter plasmid 
via sticky end ligation. pGL3 was chosen due to the luciferase coding sequence in the 
pGL3 vector which contains an upstream multiple cloning site, MCS. By cloning 
pPROX1 into the MCS of pGL3 we were able to determine whether pPROX1 has been 
activated in a selected cell line. The pPROX1 area was identified through the Ensemble 
database and through a study conducted by Zhaou et al.26 Seven versions of pPROX1 
were used before finding the correct promoter region. The ones that were used 
throughout the experiment were version 6 and version 7. They were confirmed using 
sequencing. The primers were designed making sure the Forward primer contains a 5’ 
Nhe1 digest site with a CCCC upstream sequence to aid in restriction enzyme digest. 
Alternately, the Reverse primer was designed to contain a downstream HindIII digest 
site with a 5’ CCCC sequence. By selecting Nhe1 and HindIII for a ‘sticky end’ ligation 
approach directionality of the insert upon ligation with the pGL3 vector was ensured. 
Some of the complications faced when conducting the experiment were locating a pGL3 
WT vector, a previously modified vector had to be used. The available pGL3 vector 
contained a foreign piece of DNA. Through sequencing it was confirmed that the area of 
the foreign DNA was the only modified area. The foreign insert was flanked by a NheI 
and two HindIII digest sites, therefore a double Nhe1 and HindIII digest had to be done  
followed by a phosphatase (CIP) reaction. Through performing a CIP reaction, re-
ligation of the unwanted pre-existing promoter region was prevented. Also, rather than a 
gel extraction for the vector, phenol-chloroform DNA precipitation was only done to 
maintain a high yield and prevent degradation to the vector. Another issue that was 
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faced was that the pPROX1 region contains numerous long C and G repeats which 
made PCR amplification very difficult for the upstream region. Therefore a shortened 
~2kb region that is directly upstream of the ATG codon was used. 
 
Due to early issues with the purity of the PCR product by using Promega GoGreen Taq 
polymerase and unsuccessful T4 Ligations, even after phenol-chloroform precipitation 
of the samples, we chose to first clone in the promoter regions into pCR2.1 using TA 
ligation where the vector is from a commercially pre-prepared; pCR2.1 comes linearized 
with T-overhangs.  
 
V6 and V7 were successfully TA cloned into pCR2.1. Furthermore, a successful ligation 
and transformation by screening transformant colonies using NheI and/or HindIII digest 
was confirmed. Note, pCR2.1 has a pre-existing HindIII digest site in the multiple clone 
site region, MCS, so HindIII digest alone will show a double band pattern when running 
the sample on an agarose gel electrophoresis if the promoter(s) are cloned into the 
proper forward running orientation, Figure 5a. From there we were able to transform 
our novel pCR2.1-pPROX1 v6 & v7 plasmids into competent cells and perform a 
plasmid preparation for NheI & HindIII restriction enzyme digest and agarose gel band 
extraction to continue with our ligation strategy. Once the purified digested promoters 
were obtained, sticky-end ligation using T4 DNA Ligase and the NheI+HindIII digested 
pGL3 vector was done, which was followed by transforming the ligation reactions into 
competent cells. Similar to the pCR2.1-pPROX1 v6 & v7 screening methodology, the 
potential transformant colonies were screened through NheI+HindIII restriction enzyme 
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digest of prepared plasmid samples and gel electrophoresis, and validated by 
sequencing the plasmid samples through the Penn Genomics Analysis Core. Figure 5 
 
Figure 5 Successful cloning of pPROX1 V6/V7 into pCR2.1 and pGL3 
a. 
b.  c. 
Figure 5 a. The pCR2.1vector is 4029bp or 4.0kb b. v7 is 1801 or 1.8kb, note that the forward primer’s 
consensus sequence starts 97bp upstream of V6 forward primer’s consensus sequence. pGL3 vector 
is 4818bp or 4.8kb c. V6 is 2320bp or 2.3kb 
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Transfection: 
After cloning the pGL3-pProx1 v6 and v7 vectors. The next step was to co-transfect the 
pRL vector which is wild-type Renilla luciferase (Rluc) control reporter vector, along with 
the newly constructed pGL3 vectors into 293T cells, PDLSCs, and GMSCs. However, 
similar to other stem cells, MSCs are challenging to transfect, and therefore 
standardizing a simple transfection protocol for MSCs is essential.27 In order to 
standardize a simple protocol for transfection of MSCs, we conducted a series of 
experiments to establish a protocol that does not require the use of specific expensive 
equipment or viral particles. A variety of lipofectamine products were used and a 
reporter pMAX-GFP was used to test their efficiency in 293T, PDLSCs, and GMSCs. 
Lipofectamine contains lipid subunits that can form liposomes where each product 
consists of different formulations of cationic liposomes and neutral co-lipids that have 
varying efficiencies across different cell lines. Transfections were done using 
Lipofectamine 2000, 3000, LTX, and STEM. The transfection was done in accordance 
to the provided manufacture’s protocol. They were done using various amounts of 
lipofectamine in triplicate to assess the proper volume of lipofectamine necessary for 
the highest transfection efficiency possible and the least cytotoxic effects. Transfection 
efficiency was measured by counting the total amount of cells observed in a given visual 
filed and comparing it to the amount of GFP positive cells observed within the same 
visual field, for example if n=100 cells overall were counted and 80 cells were GFP 
positive then 80/100 =80%.   
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Comparing lipofectamine transfection reagents: 
Measuring transfection efficiency using Lipofectamine Stem (LipoStem) Figure 6,7, 
Lipofectamine 2000 Figure 8, Lipofectamine LTX with PLUS Reagent Figure 9,10,11 
and Lipofectamine 3000 Figure12,13  in PDLSCs using pMAX-GFP and different 
volumes of the lipofectamine reagent as per the manufactures protocol.  
Figure 6: Lipofectamine Stem shows high cell toxicity and low transfection 
efficiency  at 1μL of lipofectamine reagent per well in a 24 well plate 
 
0 hour pre-
transfection 
  
16 hour post 
transfection 
1μL 
 
  
24 hour post 
transfection 
1μL 
 
  
Figure 6: Lipofectamine STEM results in high cell toxicity and low transfection efficiency: 40% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
 
pmax-GFP 
pmax-GFP 
 36 
 
 
 
 
 
 
 
 
 
Figure 7: Lipofectamine Stem shows high cell toxicity and low transfection 
efficiency at 1μL of lipofectamine reagent per well in a 24 well plate. 
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Figure 7: Lipofectamine STEM results in high cell toxicity and low transfection efficiency: 40% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 8: Lipofectamine 2000 shows high cell toxicity and low transfection 
efficiency at 2μL of lipofectamine reagent per well in a 24 well plate. 
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Figure 8: Lipofectamine 2000 results in high cell toxicity and low transfection efficiency: 10% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 9: Lipofectamine LTX with PLUS shows high cell toxicity and low 
transfection efficiency at 1μL of lipofectamine reagent per well in a 24 well 
plate. 
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Figure 9: Lipofectamine LTX  results in high cell toxicity and low transfection efficiency: 10% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 10: Lipofectamine LTX with PLUS shows high cell toxicity and low 
transfection efficiency at 1.5μL of lipofectamine reagent per well in a 24 well 
plate 
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Figure 10: Lipofectamine LTX  results in high cell toxicity and low transfection efficiency: 10% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 11: Lipofectamine LTX with PLUS shows high cell toxicity and low 
transfection efficiency at 2μL of lipofectamine reagent per well in a 24 well plate 
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Figure 11 : Lipofectamine LTX results in high cell toxicity and low transfection efficiency: 10% n=100. 
Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 12: Lipofectamine 3000 shows the best results in comparison to other 
lipofectamine reagents 0.75μL of lipofectamine reagent per well in a 24 well plate. 
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Figure 12: Lipofectamine 3000 shows low cell toxicity and high transfection efficiency 70% n=100 cells.  
Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 13: Lipofectamine 3000 shows the best results in comparison to other 
lipofectamine reagents when using 0.75μL of lipofectamine reagent per well in a 24 well 
plate. 1.5μL shows a decreased transfection efficiency and higher cell toxicity in 
comparison to 0.75μL of lipofectamine reagent per well in a 24 well plate. 
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Figure 13: Lipofectamine 3000 results in low cell toxicity and high transfection efficiency: 60% n =100 cells. Cells 
are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
 
 
 
 
 
 
 
pmax-GFP 
pmax-GFP 
 43 
Lipofectamine 3000 Transfection Reagent has been proven to be have the least amount 
of cell toxicity and the highest transfection efficiency in PDLSCs. To confirm this, a 
transfection was done using 0.75μL of Lipofectamine 3000 per well of a 24 well plate. 
This experiment was conducted to compare transfection efficiency across  PDLSC, 
GMSC, 293T cell lines using pMAX-GFP. Figure14,15,16,17 
 
Figure 14: 0.75μL of lipofectamine reagent per well in a 24 well plate. 
Lipofectamine 3000 - 0 hour pre-transfection 
PDLSC  
  
GMSC  
  
293T  
  
Figure14: Lipofectamine 3000 results in low cell toxicity and high transfection efficiency: 60% n=100 
cells. Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure15:Lipofectamine 3000 0.75μL of lipofectamine reagent per well in a 24 
well plate  – 24 hours post transfection. 
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Figure15: Lipofectamine 3000 0.75μL of lipofectamine reagent per well in a 24 well plate results in 
low cell toxicity and high transfection efficiency in PDLSC 70% GMSC: 80% 293T: 90% n=100 cells. 
Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure16: Lipofectamine 3000 0.75μL of lipofectamine reagent per well in a 24 
well plate  – 36 hours post transfection. 
PDLSC  
  
GMSC 
  
293T 
  
Figure16: Lipofectamine 3000 0.75μL of lipofectamine reagent per well in a 24 well plate results in 
low cell toxicity and high transfection efficiency in PDLSC 70% GMSC: 80% 293T: 90% n=100 cells. 
Cells are imaged using a 10x/0.25 objective inverted fluorescent light microscope. 
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Figure 17: Lipofectamine 3000 0.75μL of lipofectamine reagent per well in a 24 
well plate – 48 hours post transfection. 
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Figure 17 : Lipofectamine 3000 results in low cell toxicity and high transfection efficiency in PDLSC 
70% n 100 GMSC: 80% 293T: 90% n=100 cells. Cells are imaged using a 10x/0.25 objective 
inverted fluorescent light microscope. 
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Luciferase assay results: 
A successful transfection through the use of the pMAX-GFP reporter vector has been 
confirmed. Also, we were able to confirm a successful co-transfection by having a 
consistently higher firefly to renilla ratio in the pGL3-pPAN KSHV+ infected 293T 
samples when compared to its uninfected counterpart, which was expected since the 
KSHV PAN promoter is transcriptionally active in either the lytic or latent lifecycle of 
KSHV 28. Although we were able to achieve a successful transfection, with minimal 
cytotoxicity, and show that we were able to successfully perform a luciferase assay 
using pGL3-pPAN, we were unable to detect a luciferase signal above the background 
noise threshold when using pGL3-pPROX1 version 6 or 7 regardless of KSHV infection.  
Figure 18.19.20 
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Figure18: 293T: KSHV infected cells do not exhibit noticeable luciferase signal activation of 
pPROX1 at 24, 36, and 48 hours post infection. 
a. 
b.                                                                                c. 
Figure 18: a. Both v6 and v7 of the pPGL3-pPROX1 conditions did not exhibit noticeable luciferase signal. KSHV infected 293T 
cells transfected with pGL3-pPAN exhibited a positive luciferase signal compared to renilla. Most likely due to a wide variation 
of signal across samples, the results remained statistically insignificant with a p-value greater than 0.05.  
b. KSHV-infected 293T cells transfected with pGL3-pPAN showed an increase in luciferase signal compared to the uninfected 
control with a p-value less than 0.05 c. KSHV infected 293T cells transfected with pGL3-pPAN exhibited a positive luciferase 
signal compared to renilla. Due to an increase in luciferase signal in the uninfected pGL3-pPAN sample, the results remained 
statistically insignificant with a p-value greater than 0.05.  
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Figure19: PDLSCs: A slight increase in luciferase signal in KSHV+ pGL3-PROX1 v6 is observed at 24,36 
and 48 hours post infection.  
a. 
b. c. 
Figure 19: a. We observed an increase in luciferase signal with the PGL3-pPROX1 version 6 construct following KSHV infection, 
Unexpectedly, the PGL3-pPAN uninfected condition showed a higher luciferase ratio than the infected counterpart. But, both the 
uninfected and infected PGL3-PAN luciferase to renilla ratio is similar to that of the PGL3 empty vector control, suggesting that 
this observation is due to background noise. b. We see an increase in luciferase signal in KSHV+ pGL3-PROX1 v6. c. Again we 
see an increase in luciferase signal in KSHV+ pGL3-PROX1 v6, unlike the v7 conditions which exhibited a luciferase signal 
pattern opposite to our expectations. But, v6 uninfected, v7, PAN, and PGL3 empty vector all show almost similar results 
suggesting background noise interference. 
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Figure 20: GMSCs: KSHV infected cells do not exhibit noticeable luciferase signal activation of pPROX1 at 
24,36 and 48 hours 
a 
b. c. 
Figure 20: a. GMSC transfected with pGL3-pPROX1 v7 when infected with KSHV did show an increase in luciferase 
activity compared to its uninfected counterpart, but with a p-value of 0.072. b. pPAN in the KSHV+ sample showed 
an increase in luciferase signal but with high variability across samples, as shown by a wide error bar range. c. pPAN 
in the KSHV+ sample showed an increase in luciferase signal while all other samples are nearly identical to the pPGL3 
empty vector control. 
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Chapter 4 
Discussion: 
 
In this experiment two overlapping versions of the PROX1 promoter (version 6 and 
version 7) were cloned into the luciferase reporting vector pGL3. Due to technical 
constraints, promoters were cloned first into an intermediary vector pCR2.1 using TA 
cloning, after each successful clone using either pGL3 or pCR2.1. Through restriction 
enzyme digest and gel electrophoresis the transformants were confirmed, followed by 
sequencing.  
 
A method was established to calculate a viral titer in purified KSHV samples prior to 
infection. Previous equipment in the Yuan lab was replaced by a new Thermo Fisher 
Applied BioSystems Quantstudio 3 Real-Time PCR System, and therefore a new 
methodology was required prior to continuing with experiments. In order to infect 
cultures at 50 MOI using a standardized volume, we successfully were able to 
determine our viroid concentration to be 2.5x10^6 viral particles/ and visually confirmed 
infection through immunofluorescence microscopy using the GFP reporter under the 
KSHV PAN promoter, which has been previously integrated into our lab’s KSHV 
genome.   
 
Working with mesenchymal stem cells is a new set of techniques for the Yuan lab and 
we have shown that transfection using Lipofectamine 3000 with P3000 reagent resulted 
with the least cytotoxic lipofectamine reagent. Further work into determining a less 
cytotoxic method with higher transfection rates will continue to be worked on while our 
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lab continues to work with MSCs into the future. For example, Promega FuGENE or a 
lentivirus infection method may be a better approach and should be vetted in future 
attempts. Regardless, we have shown that KSHV infected 293T when transfected with 
pGL3-pPAN shows an increase in luciferase signal compared to the uninfected control. 
We were unable to consistently show an increase in the luciferase ratio using pGL3-
pPAN in uninfected versus KSHV infected PDLSCs and GMSCs. Furthermore, both 
PDLSCs, GMSCs, and 293T cells do not show a noticeable change in luciferase signal 
using both version 6 and version 7 of the PROX1 promoter when infected with KSHV.    
 
Future directions: 
The future directions for this project has many potential routes. Firstly, we should 
reassess our initial observations regarding the upregulation of PROX1 in mesenchymal 
cells following KSHV infection. We should assess for upregulation via Western Blot and 
RT-PCR. Assessing for Prox1 protein would require acquiring either a commercially 
available Prox1 antibody or purification of Prox1 for the  entire process of creating a 
usable specific antibody, including steps of immunogen preparation, immunization, 
hybridoma creation, collection, screening, isotyping, and purification through a 
commercial firm. As for the RT-PCR assay, this would require us to acquire PROX1 
specific primers that span an exon-exon junction to reduce false detection from genomic 
DNA rather than the cDNA from the biological sample.  
 
Further work needs to be done in identifying the PROX1 promoter sequence as well. 
There is very little literature regarding the promoter sequence and annotations on public 
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databases for the promoter region is limited and heavily reliant on computational 
models.  
 
First a system where we can test and dissect the promoter using promoter: reporter 
fusions should and could be established. Next we should establish that the full length 
promoter is active. We could perform a 5’ prime deletion series until activity is lost. This 
loss of function approach will identify the smallest region of the promoter that is 
necessary to induce gene expression. A gain of function assay using a limited library of 
synthetic PROX1 promoters that we have identified as the functional areas of the 
promoter should then be performed to prove biological activity, rather than implied 
computation evidence.  
 
Future work will also focus on the role of Prox1 in KSHV infected mesenchymal cells. A 
knock-down experiment of using a lentiviral shRNA approach and a separate over-
expression assay using the PROX1 CDS under an always-on promoter, or even the 
KSHV PAN promoter, followed by RNA-seq in KSHV infected and non-infected MSC 
samples would be a boon of valuable insight into the role of PROX1.  
 
Furthermore, identifying PROX1 as a therapeutic target could be done through over-
expression and/or knock-down of PROX1 in MSC-KSHV infected cell samples followed 
by renal capsule xenografting or subcutaneous pellet implantation in a murine model to 
evaluate a change in tumorigenesis. We would expect the knock-down of PROX1 to 
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reduce tumorigenesis while the upregulation of PROX1 to actually increase the rate of 
tumorigenesis given our current model and understanding. 
 
In conclusion, KS is undeniably the most common malignancy HIV patients suffer from. 
It is characterized by abnormal inflammation neoagniogensis and proliferation of spindle 
cells4,5,29. Examining the cellular origin of KS and the method in which the tumor affects 
the normal differential pathways through specific transcriptional factors like PROX1 is 
crucial to understanding the diseases progression. 
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